Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HR+/HER2-breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableLooking for participantsNCT07211178
What this trial is testing

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

Who this might be right for
Breast CancerTNBC - Triple-Negative Breast CancerHR Positive/HER-2 Negative Breast Cancer+2 more
Tempus AI 900
Testing effectiveness (Phase 2)Study completedNCT04224272
What this trial is testing

Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant

Who this might be right for
HER2+/HR+ Breast Cancer
Jazz Pharmaceuticals 51
Early research (Phase 1)Looking for participantsNCT07383506
What this trial is testing

Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

Who this might be right for
PIK3CA MutationsAdvanced Solid Tumors, AdultEndometrial Cancer+2 more
Cogent Biosciences, Inc. 90
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07189884
What this trial is testing

Pyrotinib Maleate Tablets in Combination With Dalpiciclib Isethionate Tablets and Standard Endocrine Therapy

Who this might be right for
Locally Advanced Breast Cancer (LABC)
The First Affiliated Hospital of Xiamen University 33
Not applicableNot Yet RecruitingNCT07543250
What this trial is testing

A Real-World Study of Inavolisib in Patients With HR-Positive/HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer

Who this might be right for
Breast Cancer
xuliang 100
Not applicableStudy completedNCT05452798
What this trial is testing

A Retrospective Non-interventional Study of Breast Cancer Patients Diagnosed With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Treated With Palbociclib in Denmark

Who this might be right for
Breast Cancer
Pfizer 1,054
Not applicableNot Yet RecruitingNCT07484763
What this trial is testing

Predicting Recurrence in HR+/HER2- Early Breast Cancer

Who this might be right for
Breast Cancer, HR+/HER2- Early-Stage
Shengjing Hospital 500
Large-scale testing (Phase 3)Active Not RecruitingNCT04862663
What this trial is testing

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

Who this might be right for
Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca 893
Testing effectiveness (Phase 2)Active Not RecruitingNCT04872985
What this trial is testing

Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer

Who this might be right for
Breast CancerHormone-receptor Positive Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 140
Large-scale testing (Phase 3)Study completedNCT03901339
What this trial is testing

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Gilead Sciences 543
Not applicableLooking for participantsNCT06762483
What this trial is testing

Integrated Testing Strategy for Simultaneous Detection of ESR-1 and gBRCA Mutations Via Liquid Biopsy in HR+/HER2- Metastatic Breast Cancer (mBC) Patients,

Who this might be right for
Breast Cancer, Metastatic
European Institute of Oncology 80
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07716046
What this trial is testing

Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast Cancer

Who this might be right for
Breast CancerHER2-positive Breast CancerHormone Receptor-positive Breast Cancer+1 more
Fudan University 240
Testing effectiveness (Phase 2)Looking for participantsNCT06341894
What this trial is testing

Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer

Who this might be right for
Early Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 1,163
Testing effectiveness (Phase 2)Looking for participantsNCT07426822
What this trial is testing

Rash & Diarrhea Prophylaxis With Capivasertib

Who this might be right for
Metastatic HR+/HER2- Breast Cancer
Maryam Lustberg 108
Testing effectiveness (Phase 2)Study completedNCT02732119
What this trial is testing

Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 104
Testing effectiveness (Phase 2)Looking for participantsNCT06568692
What this trial is testing

PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

Who this might be right for
Breast CancerTNBC - Triple-Negative Breast CancerHER2-negative Breast Cancer
Processa Pharmaceuticals 90
Early research (Phase 1)Study completedNCT06253195
What this trial is testing

BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorMetastatic Solid TumorHormone-receptor-positive Breast Cancer+4 more
BeOne Medicines 33
Large-scale testing (Phase 3)Looking for participantsNCT07281833
What this trial is testing

Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment

Who this might be right for
Breast CancerHR-positive Breast CancerAdvanced Breast Cancer+2 more
Women's Cancer Study Group GmbH 250
Testing effectiveness (Phase 2)Ended earlyNCT04791384
What this trial is testing

Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer

Who this might be right for
Breast Cancer
Criterium, Inc. 5
Large-scale testing (Phase 3)UnknownNCT05439499
What this trial is testing

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

Who this might be right for
Advanced Breast CancerFemale Breast Cancer
Ahon Pharmaceutical Co., Ltd. 434
Next Page